| Apr 24, 2020 | SwanBio Therapeutics | $52.0M Series A Extension | Partners Innovation Fund, Syncona | — |
| Apr 1, 2020 | ROME Therapeutics | $50.0M Series A | — | ARCH Venture Partners, Atlas Venture, GV, RA Capital, SR One, Venrock, Julius Knowles |
| Mar 1, 2020 | Akouos | $110.0M Series B | Heather Preston | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Deerfield Management, Endeavor Venture Funds, Frazier Healthcare Partners, New Enterprise Associates, Nextech Invest, OrbiMed, RA Capital, RiverVest, Seroba Life Sciences, Manny Simons, Cormorant Asset Management, Cowen Healthcare Investments, EcoR1 Capital, Fidelity Management & Research Company, Novartis, PagsGroup, Polaris Founders Capital, RA Capital Management, Sofinnova Ventures, Surveyor Capital, Wu Capital |
| Mar 1, 2020 | Affinia Therapeutics | $60.0M Series A | Atlas Venture, New Enterprise Associates, Robert Weisskoff | F-Prime Capital Partners, Ed Mathers, Alexandria Venture Investments, Lonza |
| Dec 1, 2019 | Triplet Therapeutics | $49.0M Series A | Shinichiro Fuse | Atlas Venture, OrbiMed, Alexandria Venture Investments, Invus |
| Sep 26, 2019 | ZielBio | $25.1M Series A | Jason Dinges, Meredith Fisher | — |
| Jul 1, 2019 | Amolyt Pharma | $74.0M Series A | LSP | Kurma Partners, Pontifax Venture Capital, Bpifrance, Cr, Novo Ventures, OrbiMed, Sham Innovation Sant, TAB Consulting |
| Apr 18, 2019 | Nocion Therapeutics | $27.0M Series A | Canaan Partners, F-Prime Capital | Mission BioCapital |
| Jan 1, 2019 | Keros Therapeutics | $23.0M Series B | — | Pontifax Venture Capital, Arkin Bio Ventures, Global Health Sciences Fund, Medison Pharma |
| Jul 1, 2018 | Akouos | $50.0M Series A | 5AM Ventures, New Enterprise Associates | Access Biotechnology, Canaan Partners, Connecticut Innovations, Deerfield Management, Endeavor Venture Funds, Frazier Healthcare Partners, Nextech Invest, OrbiMed, RA Capital, RiverVest, Novartis, RA Capital Management, Sofinnova Ventures |
| Nov 1, 2017 | Akouos | $8.0M Seed | 5AM Ventures, New Enterprise Associates | Access Biotechnology, Canaan Partners, Connecticut Innovations, Deerfield Management, Endeavor Venture Funds, Frazier Healthcare Partners, Nextech Invest, OrbiMed, RA Capital, RiverVest |
| Nov 17, 2016 | Syntimmune | $8.0M Series A Extension | — | Apple Tree Partners, Baxalta Ventures |
| Nov 1, 2016 | Magenta Therapeutics | $49.0M Series A | Atlas Venture, Alexis A. Borisy | UP.Partners, Access Industries, Google Ventures |
| Mar 30, 2016 | ImmuneXcite | $8.6M Series A | — | Cormorant Asset Management, Ann DeWitt |
| Mar 22, 2016 | Syntimmune | $10.0M Series A Extension | David de Graaf, Baxalta Ventures | — |
| Feb 1, 2016 | Spero Therapeutics | $30.0M Series B | — | Atlas Venture, SR One, Elliott Sigal, Timothy A. Springer, Lundbeckfond Ventures, MRL Ventures Fund, The Kraft Group |
| Jul 1, 2015 | Translate Bio | $64.0M Series B | Baupost Group, Joshua Resnick | Atlas Venture, DCVC (Data Collective), Brookside Capital, Leerink Partners, Monsanto, MS Ventures, Omega Funds, Rock Springs Capital, SR One |
| Jun 26, 2015 | Sebacia | $22.0M Debt / Series C | — | Accuitive Medical Ventures, Domain Associates, Square 1 Bank, Versant Ventures |
| Jun 1, 2015 | Spero Therapeutics | $30.0M Series A | Casper Breum | Atlas Venture, MPM Capital, Hakan Goker, RA Capital, SR One, Elliott Sigal, Timothy A. Springer, Joshua Resnick, The Kraft Group |
| May 28, 2015 | lifeIMAGE | $17.5M Other Equity | Rob Coppedge | Cardinal Partners, Galen Partners, LRVHealth, MassVentures |
| Feb 1, 2015 | Lysosomal Therapeutics | $20.0M Series A | Atlas Venture | Advent Life Sciences, Apollo Health Ventures, ARCH Venture Partners, Hatteras Venture Partners, Omega Funds, Polaris Partners, Red Tree Venture Capital, Roche Venture Fund, Vivo Capital, Bob Carpenter, Henri Termeer, Lilly Ventures, Orion Equity Partners, Roche, Sanofi Ventures |
| Oct 1, 2014 | Quartet Medicine | $17.0M Series A | Atlas Venture | Henry Skinner, Pfizer |
| Oct 1, 2014 | Raze Therapeutics | $24.0M Series A | — | ARCH Venture Partners, Atlas Venture, Hatteras Venture Partners, MPM Capital, M Ventures (Merck), Omega Funds, RA Capital, Roche Venture Fund, SV Health Investors, Astellas Venture Management, Nilesh Kumar, Novartis, Reza Halse |
| May 1, 2014 | Lysosomal Therapeutics | $5.0M Seed | Atlas Venture | Advent Life Sciences, Apollo Health Ventures, ARCH Venture Partners, Hatteras Venture Partners, Omega Funds, Polaris Partners, RA Capital, Red Tree Venture Capital, Roche Venture Fund, Vivo Capital, Steve Hall, Orion Equity Partners, Reza Halse, Carole Nuechterlein, Bernard Davitian |
| May 1, 2014 | QPID Health | $12.0M Series B | Philippe Chambon MD, PhD | Applied Ventures, Matrix, Matter Venture Partners, Cardinal Partners, Massachusetts General Physicians Organization, Matrix Partners |
